Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Injections, Subcutaneous"" wg kryterium: Temat


Tytuł :
Self-care provision of contraception: Evidence and insights from contraceptive injectable self-administration.
Autorzy :
Brady M; PATH DC Office, 455 Massachusetts Ave NW, 20001, Washington, DC, USA. Electronic address: .
Drake JK; PATH, 2201 Westlake Ave Suite 200, Seattle, 98121, WA, USA. Electronic address: .
Namagembe A; PATH Uganda Office, Plot 17, Golf Course Road, Kololo, Kampala, Uganda. Electronic address: .
Cover J; PATH, 2201 Westlake Ave Suite 200, Seattle, 98121, WA, USA. Electronic address: .
Pokaż więcej
Źródło :
Best practice & research. Clinical obstetrics & gynaecology [Best Pract Res Clin Obstet Gynaecol] 2020 Jul; Vol. 66, pp. 95-106. Date of Electronic Publication: 2020 Jan 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Injections, Subcutaneous*
Contraceptive Agents, Female/*administration & dosage
Medroxyprogesterone Acetate/*administration & dosage
Self Administration/*methods
Contraception ; Contraceptive Devices ; Female ; Humans ; Self Medication
Czasopismo naukowe
Tytuł :
A systematic study of injectable anesthetic agents in the brown anole lizard ( Anolis sagrei  ).
Autorzy :
Rasys AM; Department of Genetics, University of Georgia, Athens, GA, USA.; Department of Cellular Biology, University of Georgia, Athens, GA, USA.
Divers SJ; Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Lauderdale JD; Department of Cellular Biology, University of Georgia, Athens, GA, USA.
Menke DB; Department of Genetics, University of Georgia, Athens, GA, USA.
Pokaż więcej
Źródło :
Laboratory animals [Lab Anim] 2020 Jun; Vol. 54 (3), pp. 281-294. Date of Electronic Publication: 2019 Jul 26.
Typ publikacji :
Journal Article
MeSH Terms :
Injections, Subcutaneous*
Anesthetics/*administration & dosage
Conscious Sedation/*methods
Lizards/*physiology
Pain Management/*methods
Animals ; Female ; Random Allocation
Czasopismo naukowe
Tytuł :
Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy.
Autorzy :
Lumry W; AARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).; William Lumry, MD, is in private practice in Dallas, Texas, treating adults and children with allergic diseases and asthma. He actively participates in clinical research projects involving new treatments for asthma, allergic and immune deficiency diseases, and hereditary angioedema in his role as medical director of AARA Research Center. He is also clinical professor of internal medicine at the University of Texas Southwestern Medical School in Dallas and teaches at Parkland Memorial Hospital in Dallas. Dr Lumry is president of the Texas Allergy, Asthma and Immunology Society and a fellow of the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the American College of Physicians. He is also a member of the US Hereditary Angioedema Association Medical Advisory Board on the panels responsible for the Hereditary Angioedema International Working Group, International Consensus, and World Allergy Organization hereditary angioedema consensus documents.; Teri Templeton, LVN, was the nurse navigator and senior nurse supervisor of the US HAEA Angioedema Center at University of California San Diego, where she also served as the lead nurse on all clinical and translational research. As a public speaker and nurse educator, and through service on advisory boards, she worked to reduce the time to diagnosis and bring awareness to health care professionals on the signs and symptoms of hereditary angioedema.; Laurel Omert, MD, is currently chief medical officer at Hemanext in Lexington, Massachusetts, and a staff surgeon and intensivist at Albert Einstein Medical Center in Philadelphia. She served as medical director at CSL Behring for specialty products that included C1-INH(SC) and C1-INH(IV) during the development of this manuscript.; Donald Levy, MD, is a professor of medicine at University of California Irvine School of Medicine in Orange, California. He is very active in teaching students, residents, and fellows. He has a special interest in hereditary angioedema and conducts research in this field.
Templeton T; AARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).; William Lumry, MD, is in private practice in Dallas, Texas, treating adults and children with allergic diseases and asthma. He actively participates in clinical research projects involving new treatments for asthma, allergic and immune deficiency diseases, and hereditary angioedema in his role as medical director of AARA Research Center. He is also clinical professor of internal medicine at the University of Texas Southwestern Medical School in Dallas and teaches at Parkland Memorial Hospital in Dallas. Dr Lumry is president of the Texas Allergy, Asthma and Immunology Society and a fellow of the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the American College of Physicians. He is also a member of the US Hereditary Angioedema Association Medical Advisory Board on the panels responsible for the Hereditary Angioedema International Working Group, International Consensus, and World Allergy Organization hereditary angioedema consensus documents.; Teri Templeton, LVN, was the nurse navigator and senior nurse supervisor of the US HAEA Angioedema Center at University of California San Diego, where she also served as the lead nurse on all clinical and translational research. As a public speaker and nurse educator, and through service on advisory boards, she worked to reduce the time to diagnosis and bring awareness to health care professionals on the signs and symptoms of hereditary angioedema.; Laurel Omert, MD, is currently chief medical officer at Hemanext in Lexington, Massachusetts, and a staff surgeon and intensivist at Albert Einstein Medical Center in Philadelphia. She served as medical director at CSL Behring for specialty products that included C1-INH(SC) and C1-INH(IV) during the development of this manuscript.; Donald Levy, MD, is a professor of medicine at University of California Irvine School of Medicine in Orange, California. He is very active in teaching students, residents, and fellows. He has a special interest in hereditary angioedema and conducts research in this field.
Omert L; AARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).; William Lumry, MD, is in private practice in Dallas, Texas, treating adults and children with allergic diseases and asthma. He actively participates in clinical research projects involving new treatments for asthma, allergic and immune deficiency diseases, and hereditary angioedema in his role as medical director of AARA Research Center. He is also clinical professor of internal medicine at the University of Texas Southwestern Medical School in Dallas and teaches at Parkland Memorial Hospital in Dallas. Dr Lumry is president of the Texas Allergy, Asthma and Immunology Society and a fellow of the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the American College of Physicians. He is also a member of the US Hereditary Angioedema Association Medical Advisory Board on the panels responsible for the Hereditary Angioedema International Working Group, International Consensus, and World Allergy Organization hereditary angioedema consensus documents.; Teri Templeton, LVN, was the nurse navigator and senior nurse supervisor of the US HAEA Angioedema Center at University of California San Diego, where she also served as the lead nurse on all clinical and translational research. As a public speaker and nurse educator, and through service on advisory boards, she worked to reduce the time to diagnosis and bring awareness to health care professionals on the signs and symptoms of hereditary angioedema.; Laurel Omert, MD, is currently chief medical officer at Hemanext in Lexington, Massachusetts, and a staff surgeon and intensivist at Albert Einstein Medical Center in Philadelphia. She served as medical director at CSL Behring for specialty products that included C1-INH(SC) and C1-INH(IV) during the development of this manuscript.; Donald Levy, MD, is a professor of medicine at University of California Irvine School of Medicine in Orange, California. He is very active in teaching students, residents, and fellows. He has a special interest in hereditary angioedema and conducts research in this field.
Levy D; AARA Research Center, Dallas, Texas (Dr Lumry); US HAEA Angioedema Center at University of California San Diego, San Diego, California (Ms Templeton); CSL Behring, King of Prussia, Pennsylvania (Dr Omert); University of California Irvine School of Medicine, Orange, California (Dr Levy).; William Lumry, MD, is in private practice in Dallas, Texas, treating adults and children with allergic diseases and asthma. He actively participates in clinical research projects involving new treatments for asthma, allergic and immune deficiency diseases, and hereditary angioedema in his role as medical director of AARA Research Center. He is also clinical professor of internal medicine at the University of Texas Southwestern Medical School in Dallas and teaches at Parkland Memorial Hospital in Dallas. Dr Lumry is president of the Texas Allergy, Asthma and Immunology Society and a fellow of the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the American College of Physicians. He is also a member of the US Hereditary Angioedema Association Medical Advisory Board on the panels responsible for the Hereditary Angioedema International Working Group, International Consensus, and World Allergy Organization hereditary angioedema consensus documents.; Teri Templeton, LVN, was the nurse navigator and senior nurse supervisor of the US HAEA Angioedema Center at University of California San Diego, where she also served as the lead nurse on all clinical and translational research. As a public speaker and nurse educator, and through service on advisory boards, she worked to reduce the time to diagnosis and bring awareness to health care professionals on the signs and symptoms of hereditary angioedema.; Laurel Omert, MD, is currently chief medical officer at Hemanext in Lexington, Massachusetts, and a staff surgeon and intensivist at Albert Einstein Medical Center in Philadelphia. She served as medical director at CSL Behring for specialty products that included C1-INH(SC) and C1-INH(IV) during the development of this manuscript.; Donald Levy, MD, is a professor of medicine at University of California Irvine School of Medicine in Orange, California. He is very active in teaching students, residents, and fellows. He has a special interest in hereditary angioedema and conducts research in this field.
Pokaż więcej
Źródło :
Journal of infusion nursing : the official publication of the Infusion Nurses Society [J Infus Nurs] 2020 May/Jun; Vol. 43 (3), pp. 134-145.
Typ publikacji :
Journal Article
MeSH Terms :
Clinical Trials as Topic*
Injections, Subcutaneous*
Practice Guidelines as Topic*
Self Administration*
Angioedemas, Hereditary/*prevention & control
Complement C1 Inhibitor Protein/*administration & dosage
Angioedemas, Hereditary/drug therapy ; Humans
Czasopismo naukowe
Tytuł :
Cochlear Implantation Under Local Anesthesia With Conscious Sedation in the Elderly: First 100 Cases.
Autorzy :
Connors JR; Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, NY, USA.
Deep NL; Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, NY, USA.
Huncke TK; Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU Langone Health, New York, NY, USA.
Roland JT Jr; Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, NY, USA.
Pokaż więcej
Źródło :
The Laryngoscope [Laryngoscope] 2021 Mar; Vol. 131 (3), pp. E946-E951. Date of Electronic Publication: 2020 Jul 14.
Typ publikacji :
Journal Article
MeSH Terms :
Anesthesia, General/*adverse effects
Anesthesia, Local/*methods
Cochlear Implantation/*adverse effects
Conscious Sedation/*methods
Postoperative Complications/*epidemiology
Administration, Topical ; Aged ; Aged, 80 and over ; Anesthesia, General/economics ; Anesthesia, Local/adverse effects ; Anesthesia, Local/economics ; Conscious Sedation/adverse effects ; Conscious Sedation/economics ; Cost-Benefit Analysis ; Dexmedetomidine/administration & dosage ; Feasibility Studies ; Female ; Humans ; Hypnotics and Sedatives/administration & dosage ; Infusions, Intravenous ; Injections, Subcutaneous ; Lidocaine/administration & dosage ; Male ; Postoperative Complications/etiology ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Autorzy :
Usmani SZ; Plasma Cell Disorders Division, Clinical Research for Hematologic Malignancies, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. .
Mateos MV; University Hospital of Salamanca/IBSAL, Salamanca, Spain.
Hungria V; Clinica São Germano, São Paulo, Brazil.
Iida S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
Nahi H; Division of Hematology, Department of Medicine, Karolinska Institute, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
Magen H; Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cavo M; Department of Experimental, Diagnostic and Specialty Medicine, 'Seràgnoli' Institute of Hematology, University of Bologna, Bologna, Italy.
Hulin C; Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
White D; Dalhousie University and QEII Health Sciences Centre, Halifax, NS, Canada.
De Stefano V; Institute of Hematology, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
Fastenau J; Janssen Global Services, LLC, Raritan, NJ, USA.
Slavcev M; Janssen Global Services, LLC, Raritan, NJ, USA.
Heuck C; Janssen Research & Development, LLC, Spring House, PA, USA.
Qin X; Janssen Research & Development, LLC, Spring House, PA, USA.
Pei H; Janssen Research & Development, LLC, Spring House, PA, USA.
Masterson T; Janssen Research & Development, LLC, Spring House, PA, USA.
Lantz K; Janssen Research & Development, LLC, Spring House, PA, USA.
Gries KS; Janssen Global Services, LLC, Raritan, NJ, USA.
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Feb; Vol. 147 (2), pp. 619-631. Date of Electronic Publication: 2020 Aug 27.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Multiple Myeloma/*drug therapy
Administration, Intravenous ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Patient Satisfaction ; Recurrence ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Potential role of subcutaneous tocilizumab injections in patients with COVID-19 associated pneumonia.
Autorzy :
Greco G; Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
Ripamonti D; Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
Binda F; Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
Fabretti F; Anesthesiology Department, ASST Papa Giovanni XXIII, Bergamo, Italy.
Grazioli L; Anesthesiology Department, ASST Papa Giovanni XXIII, Bergamo, Italy.
Rizzi M; Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
Pokaż więcej
Źródło :
Journal of medical virology [J Med Virol] 2021 Feb; Vol. 93 (2), pp. 686-688. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Letter
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*complications
COVID-19/*therapy
Adult ; Aged ; Female ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged
Opinia redakcyjna
Tytuł :
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
Autorzy :
Gupta R; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
Shipa M; Department of Rheumatology, University College London, London, UK.
Yeoh SA; Department of Rheumatology, University College London, London, UK.
Buck P; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
Ehrenstein MR; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.; Department of Rheumatology, University College London, London, UK.
Pokaż więcej
Źródło :
Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2021 Feb 01; Vol. 60 (2), pp. 977-979.
Typ publikacji :
Letter
MeSH Terms :
Drug Substitution*
Patient Preference*
Abatacept/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Antirheumatic Agents/*administration & dosage
Arthritis, Rheumatoid/*drug therapy
Arthritis, Rheumatoid/physiopathology ; COVID-19 ; Decision Making, Shared ; Disease Progression ; Humans ; Infusions, Intravenous ; Injections, Subcutaneous ; SARS-CoV-2 ; Self Administration ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Autorzy :
Corren J; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. Electronic address: .
Garcia Gil E; Global Medical Respiratory, BioPharmaceuticals Research and Development, AstraZeneca, Barcelona, Spain.
Griffiths JM; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland.
Parnes JR; Amgen, Thousand Oaks, California.
van der Merwe R; AstraZeneca, Cambridge, United Kingdom.
Sałapa K; Biometrics, Late Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Warsaw, Poland.
O'Quinn S; Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland.
Pokaż więcej
Źródło :
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2021 Feb; Vol. 126 (2), pp. 187-193. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Asthmatic Agents/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Asthma/*drug therapy
Adolescent ; Adult ; Aged ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Patient Reported Outcome Measures ; Quality of Life ; Surveys and Questionnaires ; Young Adult
Czasopismo naukowe
Tytuł :
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
Autorzy :
Verma AM; Department of Gastroenterology, Kettering General Hospital, Kettering NN16 8UZ, UK. Electronic address: .
Patel A; Department of Gastroenterology, Kettering General Hospital, Kettering NN16 8UZ, UK.
Subramanian S; Department of Gastroenterology and Hepatology, Liverpool University Hospitals Foundation NHS Trust, Liverpool, UK.
Smith PJ; Department of Gastroenterology and Hepatology, Liverpool University Hospitals Foundation NHS Trust, Liverpool, UK.
Pokaż więcej
Źródło :
The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Feb; Vol. 6 (2), pp. 88-89.
Typ publikacji :
Letter
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Gastrointestinal Agents/*administration & dosage
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*administration & dosage
Antibodies, Monoclonal/therapeutic use ; COVID-19/prevention & control ; Gastrointestinal Agents/therapeutic use ; Humans ; Infliximab/therapeutic use ; Infusions, Intravenous ; Injections, Subcutaneous ; Self Administration ; United Kingdom
Opinia redakcyjna
Tytuł :
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
Autorzy :
Zhang H; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Li C; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Liu J; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Wu M; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Li X; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Zhu X; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Li Q; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Wang B; Feiyang Biotechnology (Jilin) Co. Ltd ., China.
Mao Y; Feiyang Biotechnology (Jilin) Co. Ltd ., China.
Ding Y; Phase I Clinical Research Center, The First Hospital of Jilin University , Jilin, China.
Jin Q; Department of Hepatology, The First Hospital of Jilin University , Jilin, China.
Pokaż więcej
Źródło :
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2021 Feb; Vol. 30 (2), pp. 185-192. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :
Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Biosimilar Pharmaceuticals/*pharmacokinetics
Bone Density Conservation Agents/*pharmacokinetics
Denosumab/*pharmacokinetics
Adult ; Biosimilar Pharmaceuticals/administration & dosage ; Biosimilar Pharmaceuticals/adverse effects ; Bone Density Conservation Agents/administration & dosage ; Bone Density Conservation Agents/adverse effects ; China ; Denosumab/administration & dosage ; Denosumab/adverse effects ; Double-Blind Method ; Female ; Healthy Volunteers ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Patient Safety ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł :
The Effects of Subcutaneously Injected Novel Biphasic Cross-Linked Hyaluronic Acid Filler: In Vivo Study.
Autorzy :
Hahn HM; Department of Plastic and Reconstructive Surgery, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea.
Lee WB; Department of Plastic and Reconstructive Surgery, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea.
Lee IJ; Department of Plastic and Reconstructive Surgery, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Republic of Korea. .
Pokaż więcej
Źródło :
Aesthetic plastic surgery [Aesthetic Plast Surg] 2021 Feb; Vol. 45 (1), pp. 322-331. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cosmetic Techniques*
Dermal Fillers*
Animals ; Elasticity ; Hyaluronic Acid ; Injections, Subcutaneous ; Mice ; Skin
Czasopismo naukowe
Tytuł :
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
Autorzy :
Mease PJ; Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA .
Helliwell PS; Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Hjuler KF; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Raymond K; Medical Department, Leo Pharma, Ballerup, Denmark.
McInnes I; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło :
Annals of the rheumatic diseases [Ann Rheum Dis] 2021 Feb; Vol. 80 (2), pp. 185-193. Date of Electronic Publication: 2020 Oct 26.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Arthritis, Psoriatic/*drug therapy
Receptors, Interleukin-17/*antagonists & inhibitors
Adolescent ; Adult ; Arthritis, Psoriatic/immunology ; Double-Blind Method ; Female ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Severity of Illness Index ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Coupling Liquid Chromatography and Tandem Mass Spectrometry to Electrophoresis for In-Depth Analysis of Glycosaminoglycan Drugs: Heparin and the Multicomponent Sulodexide.
Autorzy :
Sheng A; National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Chen Q; National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Yu M; National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Xiao R; National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Zhang T; College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.; Division of Chemistry and Analytical Science, National Institute of Metrology, Beijing 100029, China.
Wang Z; Department of Virology, School of Public Health, Shandong University, Jinan 250012, China.
Linhardt RJ; Department of Chemistry and Chemical Biology, Department of Chemical and Biological Engineering, Department of Biology, and Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180, United States.
Sun X; Collaborative Innovation Center for Green Chemical Manufacturing and Accurate Detection, School of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.
Jin L; National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Chi L; National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Pokaż więcej
Źródło :
Analytical chemistry [Anal Chem] 2021 Jan 26; Vol. 93 (3), pp. 1433-1442. Date of Electronic Publication: 2020 Dec 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Glycosaminoglycans/*analysis
Heparin/*analysis
Administration, Oral ; Chromatography, Liquid ; Electrophoresis ; Glycosaminoglycans/administration & dosage ; Heparin/administration & dosage ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
Myeloradiculoneuropathy due to vitamin B 12 deficiency: an unusual clinical and radiological presentation.
Autorzy :
Das S; Neurology, Institute of Postgraduate Medical Education and Research, Bangur Institute of Neurosciences, Kolkata, West Bengal, India.
Dubey S; Neurology, Institute of Postgraduate Medical Education and Research, Bangur Institute of Neurosciences, Kolkata, West Bengal, India .
Pandit A; Neurology, Institute of Postgraduate Medical Education and Research, Bangur Institute of Neurosciences, Kolkata, West Bengal, India.
Ray BK; Neurology, Institute of Postgraduate Medical Education and Research, Bangur Institute of Neurosciences, Kolkata, West Bengal, India.
Pokaż więcej
Źródło :
BMJ case reports [BMJ Case Rep] 2021 Jan 25; Vol. 14 (1). Date of Electronic Publication: 2021 Jan 25.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Spinal Cord/*diagnostic imaging
Subacute Combined Degeneration/*diagnosis
Vitamin B 12 Deficiency/*diagnosis
Adult ; Cognitive Dysfunction/physiopathology ; Electrodiagnosis ; Electromyography ; Humans ; Injections, Subcutaneous ; Magnetic Resonance Imaging ; Male ; Neural Conduction ; Polyradiculoneuropathy/physiopathology ; Quadriplegia/physiopathology ; Spinal Cord Diseases/physiopathology ; Subacute Combined Degeneration/drug therapy ; Subacute Combined Degeneration/physiopathology ; Treatment Outcome ; Urinary Retention/physiopathology ; Vitamin B 12/analogs & derivatives ; Vitamin B 12/therapeutic use ; Vitamin B 12 Deficiency/drug therapy ; Vitamin B 12 Deficiency/physiopathology ; Vitamin B Complex/therapeutic use
Czasopismo naukowe
Tytuł :
The Effect of 3-Month Growth Hormone Administration and 12-Month Follow-Up Duration among Heart Failure Patients Four Weeks after Myocardial Infarction: A Randomized Double-Blinded Clinical Trial.
Autorzy :
Amirpour A; Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Vakhshoori M; Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Zavar R; Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Zarei H; Chamran Hospital, Department of Critical Care Nursing, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.
Sadeghi M; Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Yavari B; Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Pokaż więcej
Źródło :
Cardiovascular therapeutics [Cardiovasc Ther] 2021 Jan 23; Vol. 2021, pp. 2680107. Date of Electronic Publication: 2021 Jan 23 (Print Publication: 2021).
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Heart Failure/*drug therapy
Human Growth Hormone/*administration & dosage
Myocardial Infarction/*complications
Stroke Volume/*drug effects
Ventricular Function, Left/*drug effects
Adult ; Aged ; Double-Blind Method ; Drug Administration Schedule ; Heart Failure/etiology ; Heart Failure/physiopathology ; Humans ; Injections, Subcutaneous ; Iran ; Male ; Middle Aged ; Myocardial Infarction/physiopathology ; Myocardial Infarction/therapy ; Pilot Projects ; Recovery of Function ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial.
Autorzy :
Mansour E; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Bueno FF; Obesity and Comorbidities Research Center, University of Campinas, Campinas, São Paulo, Brazil.
de Lima-Júnior JC; Obesity and Comorbidities Research Center, University of Campinas, Campinas, São Paulo, Brazil.
Palma A; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Monfort-Pires M; Obesity and Comorbidities Research Center, University of Campinas, Campinas, São Paulo, Brazil.
Bombassaro B; Obesity and Comorbidities Research Center, University of Campinas, Campinas, São Paulo, Brazil.
Araujo EP; Obesity and Comorbidities Research Center, University of Campinas, Campinas, São Paulo, Brazil.; School of Nursing, University of Campinas, Campinas, São Paulo, Brazil.
Bernardes AF; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Ulaf RG; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Nunes TA; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Ribeiro LC; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Falcão ALE; Department of Surgery, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Santos TM; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Trabasso P; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Dertkigil RP; Department of Radiology, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Dertkigil SS; Department of Radiology, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Maia RP; Department of Statistics, Institute of Mathematics, Statistics, and Scientific Computation, University of Campinas, Campinas, São Paulo, Brazil.
Benaglia T; Department of Statistics, Institute of Mathematics, Statistics, and Scientific Computation, University of Campinas, Campinas, São Paulo, Brazil.
Moretti ML; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Velloso LA; Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil. .; Obesity and Comorbidities Research Center, University of Campinas, Campinas, São Paulo, Brazil. .
Pokaż więcej
Źródło :
Trials [Trials] 2021 Jan 20; Vol. 22 (1), pp. 71. Date of Electronic Publication: 2021 Jan 20.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Bradykinin/*analogs & derivatives
COVID-19/*drug therapy
Complement C1 Inhibitor Protein/*administration & dosage
Respiratory Insufficiency/*drug therapy
Adult ; Angiotensin-Converting Enzyme 2/metabolism ; Bradykinin/administration & dosage ; Bradykinin/adverse effects ; Bradykinin/antagonists & inhibitors ; Bradykinin/immunology ; Bradykinin/metabolism ; Bradykinin B2 Receptor Antagonists/administration & dosage ; Bradykinin B2 Receptor Antagonists/adverse effects ; Brazil ; COVID-19/complications ; COVID-19/immunology ; COVID-19/virology ; Clinical Trials, Phase II as Topic ; Complement C1 Inhibitor Protein/adverse effects ; Drug Administration Schedule ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; Kallikreins/antagonists & inhibitors ; Kallikreins/metabolism ; Randomized Controlled Trials as Topic ; Respiratory Insufficiency/immunology ; Respiratory Insufficiency/virology ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/pathogenicity ; Severity of Illness Index ; Treatment Outcome
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Autorzy :
Klein AL; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Imazio M; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Cremer P; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Brucato A; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Abbate A; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Fang F; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Insalaco A; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
LeWinter M; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Lewis BS; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Lin D; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Luis SA; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Nicholls SJ; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Pano A; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Wheeler A; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Paolini JF; From the Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland (A.L.K., P.C.); University Cardiology, Cardiovascular, and Thoracic Department, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino and University of Turin, Turin (M.I.), the Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan (A.B.), and the Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome (A.I.) - all in Italy; Pauley Heart Center, Virginia Commonwealth University, Richmond (A.A.); Kiniksa Pharmaceuticals, Lexington, MA (F.F., A.P., J.F.P.); the Cardiology Unit, University of Vermont Medical Center, Burlington (M.L.); the Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.); the Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis (D.L.), and the Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester (S.A.L.) - both in Minnesota; the Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, VIC, Australia (S.J.N.); and Kiniksa Pharmaceuticals, Hamilton, Bermuda (A.W.).
Pokaż więcej
Corporate Authors :
RHAPSODY Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jan 07; Vol. 384 (1), pp. 31-41. Date of Electronic Publication: 2020 Nov 16.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Pericarditis/*drug therapy
Receptors, Interleukin-1 Type I/*antagonists & inhibitors
Recombinant Fusion Proteins/*therapeutic use
Adolescent ; Adult ; Aged ; Double-Blind Method ; Female ; Humans ; Injections, Subcutaneous/adverse effects ; Interleukin-1alpha ; Interleukin-1beta ; Male ; Middle Aged ; Proportional Hazards Models ; Recombinant Fusion Proteins/adverse effects ; Recurrence ; Respiratory Tract Infections/etiology ; Young Adult
Czasopismo naukowe
Tytuł :
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.
Autorzy :
Di Nisio M; Department of Medicine and Ageing Sciences, University G. D'Annunzio, Chieti-Pescara, Italy; Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. Electronic address: .
Potere N; Department of Internal Medicine, 'G. D'Annunzio' University, Chieti, Italy.
Candeloro M; Department of Medicine and Ageing Sciences, University G. D'Annunzio, Chieti-Pescara, Italy.
Spacone A; Respiratory Medicine Unit, Pescara General Hospital, Pescara, Italy.
Pieramati L; Department of Internal Medicine, 'G. D'Annunzio' University, Chieti, Italy. Electronic address: .
Ferrandu G; Internal Medicine Unit, Pescara General Hospital, Pescara, Italy. Electronic address: .
Rizzo G; Department of Internal Medicine, 'G. D'Annunzio' University, Chieti, Italy.
La Vella M; Department of Internal Medicine, 'G. D'Annunzio' University, Chieti, Italy.
Di Carlo S; Geriatric Medicine Unit, Pescara General Hospital, Pescara, Italy. Electronic address: .
Cibelli D; Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy. Electronic address: .
Parruti G; Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.
Levi M; Cardiometabolic Programme, National Institute for Health Research University College London Hospitals (UCLH) Biomedical Research Centre, Department of Medicine, UCLH National Health Service Foundation Trust, London NW1 2PG, UK. Electronic address: .
Porreca E; Department of Medical, Oral and Biotechnological Sciences, 'G. D'Annunzio' University, Chieti, Italy. Electronic address: .
Pokaż więcej
Źródło :
European journal of internal medicine [Eur J Intern Med] 2021 Jan; Vol. 83, pp. 34-38. Date of Electronic Publication: 2020 Nov 03.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Blood Coagulation/*physiology
COVID-19/*blood
COVID-19/*drug therapy
COVID-19/*therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Adult ; Aged ; Blood Cell Count ; Blood Coagulation Tests ; C-Reactive Protein ; Cohort Studies ; Combined Modality Therapy ; Female ; Hospitalization ; Humans ; Injections, Subcutaneous ; Italy ; Male ; Middle Aged
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Autorzy :
Tan AR; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Electronic address: .
Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Mattar A; Hospital Pérola Byington, São Paulo, Brazil.
Colomer R; Hospital Universitario La Princesa, Madrid, Spain.
Stroyakovskii D; City Clinical Oncology Hospital 62, Moscow, Russia.
Nowecki Z; Centrum Onkologii-Instytut, Warsaw, Poland.
De Laurentiis M; Istituto Nazionale Tumori IRCCS 'Fondazione Pascale', Napoli, Italy.
Pierga JY; Institut Curie and Université de Paris, Paris, France.
Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Schem C; Mammazentrum Hamburg, Hamburg, Germany.
Hogea A; Roche Products, Welwyn Garden City, UK.
Badovinac Crnjevic T; F Hoffmann-La Roche, Basel, Switzerland.
Heeson S; Roche Products, Welwyn Garden City, UK.
Shivhare M; Roche Products, Welwyn Garden City, UK.
Kirschbrown WP; Genentech, South San Francisco, CA, USA.
Restuccia E; F Hoffmann-La Roche, Basel, Switzerland.
Jackisch C; Sana Klinikum Offenbach, Offenbach, Germany.
Pokaż więcej
Corporate Authors :
FeDeriCa study group
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Jan; Vol. 22 (1), pp. 85-97. Date of Electronic Publication: 2020 Dec 21.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*analysis
Breast Neoplasms/*drug therapy
Receptor, ErbB-2/*analysis
Trastuzumab/*administration & dosage
Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Breast Neoplasms/chemistry ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Female ; Humans ; Hyaluronoglucosaminidase/administration & dosage ; Injections, Subcutaneous ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Time Factors ; Trastuzumab/adverse effects ; Trastuzumab/pharmacokinetics ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies